OTCMKTS:CBWTF

Auxly Cannabis Group Competitors

$0.17

-0.10 (-36.87 %)

(As of 10/21/2020 12:00 AM ET)

Add

Compare

Today's Range

$0.17

Now: $0.17▼

$0.28

50-Day Range

$0.09

MA: $0.13▼

$0.27

52-Week Range

$0.08

Now: $0.17▼

$0.59

Volume5.40 million shs

Average Volume1.03 million shs

Market Capitalization$109.89 million

P/E RatioN/A

Dividend YieldN/A

Beta0.62

Auxly Cannabis Group (OTCMKTS:CBWTF) Vs. SPHRY, AVXL, LUNA, PIRS, ELOX, and BIOQ

Should you be buying CBWTF stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Auxly Cannabis Group, including STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), and BIOQUAL (BIOQ).

Auxly Cannabis Group vs. STARPHARMA HOLD/S Stock

STARPHARMA HOLD/S (OTCMKTS:SPHRY) and Auxly Cannabis Group (OTCMKTS:CBWTF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares STARPHARMA HOLD/S and Auxly Cannabis Group's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STARPHARMA HOLD/S	$4.40 million	96.93	$-9,860,000.00	N/A	N/A
Auxly Cannabis Group	$6.29 million	17.47	$-77,300,000.00	N/A	N/A

STARPHARMA HOLD/S has higher earnings, but lower revenue than Auxly Cannabis Group.

Profitability

This table compares STARPHARMA HOLD/S and Auxly Cannabis Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
STARPHARMA HOLD/S	N/A	N/A	N/A
Auxly Cannabis Group	-531.54%	-47.44%	-28.11%

Analyst Ratings

This is a breakdown of recent ratings for STARPHARMA HOLD/S and Auxly Cannabis Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STARPHARMA HOLD/S	0	0	0	0	N/A
Auxly Cannabis Group	0	0	2	0	3.00

Auxly Cannabis Group has a consensus price target of $0.40, suggesting a potential upside of 133.64%. Given Auxly Cannabis Group's higher probable upside, analysts plainly believe Auxly Cannabis Group is more favorable than STARPHARMA HOLD/S.

Risk & Volatility

STARPHARMA HOLD/S has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Auxly Cannabis Group has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

STARPHARMA HOLD/S beats Auxly Cannabis Group on 6 of the 10 factors compared between the two stocks.

Auxly Cannabis Group vs. Anavex Life Sciences Stock

Auxly Cannabis Group (OTCMKTS:CBWTF) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Auxly Cannabis Group and Anavex Life Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auxly Cannabis Group	-531.54%	-47.44%	-28.11%
Anavex Life Sciences	N/A	-101.10%	-81.05%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Comparatively, 19.8% of Anavex Life Sciences shares are held by institutional investors. 12.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Anavex Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auxly Cannabis Group	0	0	2	0	3.00
Anavex Life Sciences	0	0	5	0	3.00

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Anavex Life Sciences has a consensus price target of $12.00, indicating a potential upside of 133.01%. Given Auxly Cannabis Group's higher probable upside, equities analysts plainly believe Auxly Cannabis Group is more favorable than Anavex Life Sciences.

Valuation and Earnings

This table compares Auxly Cannabis Group and Anavex Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auxly Cannabis Group	$6.29 million	17.47	$-77,300,000.00	N/A	N/A
Anavex Life Sciences	N/A	N/A	$-26,300,000.00	($0.50)	-10.30

Anavex Life Sciences has lower revenue, but higher earnings than Auxly Cannabis Group.

Summary

Anavex Life Sciences beats Auxly Cannabis Group on 6 of the 11 factors compared between the two stocks.

Auxly Cannabis Group vs. Luna Innovations Stock

Auxly Cannabis Group (OTCMKTS:CBWTF) and Luna Innovations (NASDAQ:LUNA) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Auxly Cannabis Group and Luna Innovations' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auxly Cannabis Group	-531.54%	-47.44%	-28.11%
Luna Innovations	4.93%	7.50%	5.86%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Comparatively, 44.0% of Luna Innovations shares are held by institutional investors. 11.2% of Luna Innovations shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Luna Innovations, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auxly Cannabis Group	0	0	2	0	3.00
Luna Innovations	0	1	1	0	2.50

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Luna Innovations has a consensus price target of $8.00, indicating a potential upside of 16.79%. Given Auxly Cannabis Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Auxly Cannabis Group is more favorable than Luna Innovations.

Valuation and Earnings

This table compares Auxly Cannabis Group and Luna Innovations' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auxly Cannabis Group	$6.29 million	17.47	$-77,300,000.00	N/A	N/A
Luna Innovations	$70.52 million	2.99	$5.34 million	$0.17	40.29

Luna Innovations has higher revenue and earnings than Auxly Cannabis Group.

Summary

Luna Innovations beats Auxly Cannabis Group on 9 of the 13 factors compared between the two stocks.

Auxly Cannabis Group vs. Pieris Pharmaceuticals Stock

Auxly Cannabis Group (OTCMKTS:CBWTF) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Auxly Cannabis Group and Pieris Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auxly Cannabis Group	-531.54%	-47.44%	-28.11%
Pieris Pharmaceuticals	-25.90%	-35.00%	-11.81%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Comparatively, 65.5% of Pieris Pharmaceuticals shares are held by institutional investors. 5.7% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Pieris Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auxly Cannabis Group	0	0	2	0	3.00
Pieris Pharmaceuticals	0	0	3	0	3.00

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Pieris Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 224.83%. Given Pieris Pharmaceuticals' higher probable upside, analysts plainly believe Pieris Pharmaceuticals is more favorable than Auxly Cannabis Group.

Valuation and Earnings

This table compares Auxly Cannabis Group and Pieris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auxly Cannabis Group	$6.29 million	17.47	$-77,300,000.00	N/A	N/A
Pieris Pharmaceuticals	$46.28 million	2.44	$-25,470,000.00	($0.56)	-3.85

Pieris Pharmaceuticals has higher revenue and earnings than Auxly Cannabis Group.

Summary

Pieris Pharmaceuticals beats Auxly Cannabis Group on 10 of the 12 factors compared between the two stocks.

Auxly Cannabis Group vs. Eloxx Pharmaceuticals Stock

Auxly Cannabis Group (OTCMKTS:CBWTF) and Eloxx Pharmaceuticals (OTCMKTS:ELOX) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Eloxx Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auxly Cannabis Group	0	0	2	0	3.00
Eloxx Pharmaceuticals	0	2	3	0	2.60

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Eloxx Pharmaceuticals has a consensus price target of $5.80, indicating a potential upside of 107.14%. Given Auxly Cannabis Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Auxly Cannabis Group is more favorable than Eloxx Pharmaceuticals.

Valuation and Earnings

This table compares Auxly Cannabis Group and Eloxx Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auxly Cannabis Group	$6.29 million	17.47	$-77,300,000.00	N/A	N/A
Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Auxly Cannabis Group.

Profitability

This table compares Auxly Cannabis Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auxly Cannabis Group	-531.54%	-47.44%	-28.11%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. 44.0% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats Auxly Cannabis Group on 5 of the 9 factors compared between the two stocks.

Auxly Cannabis Group vs. BIOQUAL Stock

Auxly Cannabis Group (OTCMKTS:CBWTF) and BIOQUAL (OTCMKTS:BIOQ) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares Auxly Cannabis Group and BIOQUAL's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auxly Cannabis Group	$6.29 million	17.47	$-77,300,000.00	N/A	N/A
BIOQUAL	$46.36 million	1.34	$4.23 million	N/A	N/A

BIOQUAL has higher revenue and earnings than Auxly Cannabis Group.

Profitability

This table compares Auxly Cannabis Group and BIOQUAL's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auxly Cannabis Group	-531.54%	-47.44%	-28.11%
BIOQUAL	9.13%	16.17%	8.85%

Analyst Ratings

This is a breakdown of current ratings for Auxly Cannabis Group and BIOQUAL, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auxly Cannabis Group	0	0	2	0	3.00
BIOQUAL	0	0	0	0	N/A

Auxly Cannabis Group currently has a consensus price target of $0.40, suggesting a potential upside of 133.64%. Given Auxly Cannabis Group's higher probable upside, analysts plainly believe Auxly Cannabis Group is more favorable than BIOQUAL.

Institutional & Insider Ownership

0.0% of Auxly Cannabis Group shares are owned by institutional investors. 39.2% of BIOQUAL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, BIOQUAL has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500.

Summary

BIOQUAL beats Auxly Cannabis Group on 7 of the 12 factors compared between the two stocks.